Drug intelligence / Profile preview

SIM0317

Development stage: Preclinical
Lead developer: Jiangsu Simsheng Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIM0317 is an antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17), developed by Simcere Pharmaceutical (Jiangsu Xiansheng). CDH17 is a calcium-dependent cell adhesion protein that is highly and specifically expressed in gastrointestinal (GI) tract epithelia and is overexpressed in various GI malignancies, including colorectal and gastric cancers. By targeting CDH17, SIM0317 aims to selectively deliver a potent cytotoxic agent to tumor cells while sparing healthy tissue. This program is part of Simcere's broader portfolio of CDH17-targeted therapies intended for the treatment of advanced solid tumors, particularly those of the gastrointestinal tract.

Targets

CDH17 (Cadherin-17)

Beyond the preview

Go deeper on SIM0317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0317.

Explore the full profile